JP2007500005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007500005A5 JP2007500005A5 JP2006521655A JP2006521655A JP2007500005A5 JP 2007500005 A5 JP2007500005 A5 JP 2007500005A5 JP 2006521655 A JP2006521655 A JP 2006521655A JP 2006521655 A JP2006521655 A JP 2006521655A JP 2007500005 A5 JP2007500005 A5 JP 2007500005A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- treated
- per day
- rosuvastatin
- statins
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 17
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 14
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 11
- 229960000672 rosuvastatin Drugs 0.000 claims description 11
- 101000836291 Homo sapiens Solute carrier organic anion transporter family member 1B1 Proteins 0.000 claims description 9
- 102100027233 Solute carrier organic anion transporter family member 1B1 Human genes 0.000 claims description 9
- 235000004279 alanine Nutrition 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 5
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 238000004448 titration Methods 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 239000000523 sample Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000004474 valine Substances 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 4
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 101100533800 Homo sapiens SLCO1B1 gene Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317592.4A GB0317592D0 (en) | 2003-07-26 | 2003-07-26 | Method |
| PCT/GB2004/003236 WO2005012566A2 (en) | 2003-07-26 | 2004-07-26 | Use of polymorphisis in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007500005A JP2007500005A (ja) | 2007-01-11 |
| JP2007500005A5 true JP2007500005A5 (https=) | 2007-09-13 |
| JP4166257B2 JP4166257B2 (ja) | 2008-10-15 |
Family
ID=27772801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006521655A Expired - Fee Related JP4166257B2 (ja) | 2003-07-26 | 2004-07-26 | ヒトにおけるスタチン薬物動態に対する効果と関連するヒトｏａｔｐ−ｃにおける多型のスタチン療法での使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7700277B2 (https=) |
| EP (1) | EP1651774B1 (https=) |
| JP (1) | JP4166257B2 (https=) |
| AT (1) | ATE373730T1 (https=) |
| CY (1) | CY1107801T1 (https=) |
| DE (1) | DE602004009083T2 (https=) |
| DK (1) | DK1651774T3 (https=) |
| ES (1) | ES2291899T3 (https=) |
| GB (1) | GB0317592D0 (https=) |
| PL (1) | PL1651774T3 (https=) |
| PT (1) | PT1651774E (https=) |
| WO (1) | WO2005012566A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080269188A1 (en) * | 2004-07-21 | 2008-10-30 | Inserm | Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy |
| JP2011512813A (ja) * | 2008-02-29 | 2011-04-28 | アイシス イノベーション リミテッド | 診断法 |
| US9817001B2 (en) | 2008-05-27 | 2017-11-14 | Boston Heart Diagnostics Corporation | Methods for determining LDL cholesterol treatment |
| US8470541B1 (en) | 2008-09-27 | 2013-06-25 | Boston Heart Diagnostics Corporation | Methods for separation and immuno-detection of biomolecules, and apparatus related thereto |
| US8765377B2 (en) | 2011-10-13 | 2014-07-01 | Boston Heart Diagnostics Corporation | Compositions and methods for treating and preventing coronary heart disease |
| US9828624B2 (en) | 2013-07-24 | 2017-11-28 | Boston Heart Diagnostics Corporation | Driving patient compliance with therapy |
| CA2968221A1 (en) | 2014-11-17 | 2016-05-26 | Boston Heart Diagnostic Corporation | Cardiovascular disease risk assessment |
| US10572811B2 (en) | 2015-01-29 | 2020-02-25 | Splunk Inc. | Methods and systems for determining probabilities of occurrence for events and determining anomalous events |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| CN110904215A (zh) * | 2019-12-16 | 2020-03-24 | 西安和合医学检验所有限公司 | 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) * | 1861-04-09 | Coffee-pot | ||
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) * | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) * | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) * | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4902614A (en) * | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| GB8902689D0 (en) | 1989-02-07 | 1989-03-30 | Ici Plc | Assay method |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| JP4071277B2 (ja) | 1993-11-12 | 2008-04-02 | ピーエイチアールアイ・プロパティーズ・インコーポレーテッド | 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット |
| EP1141282A2 (en) | 1998-08-07 | 2001-10-10 | Axys Pharmaceuticals, Inc. | Human anion transporter genes atnov |
| US20020090622A1 (en) * | 2000-08-23 | 2002-07-11 | Monisola Adeokun | Chemical compounds |
-
2003
- 2003-07-26 GB GBGB0317592.4A patent/GB0317592D0/en not_active Ceased
-
2004
- 2004-07-26 DK DK04743565T patent/DK1651774T3/da active
- 2004-07-26 DE DE602004009083T patent/DE602004009083T2/de not_active Expired - Lifetime
- 2004-07-26 PL PL04743565T patent/PL1651774T3/pl unknown
- 2004-07-26 EP EP04743565A patent/EP1651774B1/en not_active Expired - Lifetime
- 2004-07-26 AT AT04743565T patent/ATE373730T1/de active
- 2004-07-26 US US10/566,054 patent/US7700277B2/en not_active Expired - Fee Related
- 2004-07-26 PT PT04743565T patent/PT1651774E/pt unknown
- 2004-07-26 JP JP2006521655A patent/JP4166257B2/ja not_active Expired - Fee Related
- 2004-07-26 WO PCT/GB2004/003236 patent/WO2005012566A2/en not_active Ceased
- 2004-07-26 ES ES04743565T patent/ES2291899T3/es not_active Expired - Lifetime
-
2007
- 2007-11-14 CY CY20071101470T patent/CY1107801T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Melzer et al. | A genome-wide association study identifies protein quantitative trait loci (pQTLs) | |
| Canaparo et al. | Expression of CYP3A isoforms and P‐glycoprotein in human stomach, jejunum and ileum | |
| Han et al. | Genome-wide association reveals genetic effects on human Aβ 42 and τ protein levels in cerebrospinal fluids: a case control study | |
| Salem et al. | Chromogranin A polymorphisms are associated with hypertensive renal disease | |
| Green et al. | P2RX7: a bipolar and unipolar disorder candidate susceptibility gene? | |
| Prata et al. | Association of DAO and G72 (DAOA)/G30 genes with bipolar affective disorder | |
| Hirvensalo et al. | UGT1A3 and sex are major determinants of telmisartan pharmacokinetics—a comprehensive pharmacogenomic study | |
| JP2016540729A5 (https=) | ||
| JP2007500005A5 (https=) | ||
| Kang et al. | Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia | |
| Jones et al. | Evaluating a causal relationship between complement factor I protein level and advanced age-related macular degeneration using mendelian randomization | |
| Niessner et al. | Fractalkine receptor polymorphisms V249I and T280M as genetic risk factors for restenosis | |
| Akomolafe et al. | Genetic association between endothelial nitric oxide synthase and Alzheimer disease | |
| Zuo et al. | The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation | |
| AU773765B2 (en) | Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele | |
| JP4166257B2 (ja) | ヒトにおけるスタチン薬物動態に対する効果と関連するヒトｏａｔｐ−ｃにおける多型のスタチン療法での使用 | |
| Lai et al. | Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia | |
| Korovaitseva et al. | Alpha-2 macroglobulin gene in early-and late-onset Alzheimer disease | |
| Calle et al. | Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76 | |
| Ali et al. | Association study of Klotho gene polymorphism with calcium oxalate stones in the Uyghur population of Xinjiang, China | |
| Li et al. | Significance of sarcomere gene mutation in patients with dilated cardiomyopathy | |
| KR101883631B1 (ko) | 심장 질환 후 우울증 진단을 위한 정보 제공 방법 및 진단용 키트 | |
| Alina et al. | Thr92Ala polymorphism of human type 2 deiodinase gene (hD2) affects the development of Graves′ disease, treatment efficiency, and rate of remission | |
| Tranah et al. | Mitochondrial DNA m. 13514G> A heteroplasmy is associated with depressive symptoms in the elderly | |
| Matsumoto et al. | Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans |